Page last updated: 2024-12-07

dicentrine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dicentrine is an aporphine alkaloid found in plants of the genus Dicentra, such as Dicentra cucullaria (Dutchman's breeches) and Dicentra spectabilis (Bleeding heart). It exhibits a wide range of pharmacological activities, including anti-inflammatory, anti-nociceptive, and anti-tumor effects. Dicentrine has been shown to inhibit the production of pro-inflammatory cytokines and mediators, as well as to block the activation of the NLRP3 inflammasome, a key player in inflammation. Its anti-nociceptive effects have been attributed to its ability to modulate the activity of opioid receptors and voltage-gated sodium channels. Dicentrine has also been reported to have anti-tumor activity, possibly through its ability to induce apoptosis and inhibit cell proliferation in cancer cells. Research on dicentrine is ongoing to further understand its mechanisms of action and explore its potential as a therapeutic agent for various diseases.'

dicentrine: structure given in first source; RN refers to (S)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID101300
CHEMBL ID464748
CHEBI ID81079
SCHEMBL ID6369440
MeSH IDM0184618
PubMed CID317843
CHEMBL ID478754
MeSH IDM0184618

Synonyms (71)

Synonym
ccris 3806
6aalpha-aporphine, 9,10-dimethoxy-1,2-(methylenedioxy)-
6a-alpha-aporphine, 9,10-dimethoxy-1,2-(methylenedioxy)-
d-dicentrine
1,2-methylenedioxy-9,10-dimethoxyaporphine
brn 0095476
9,10-dimethoxy-1,2-(methylenedioxy)aporphine
5h-benzo(g)-1,3-benzodioxolo(6,5,4-de)quinoline, 6,7,7a,8-tetrahydro-10,11-dimethoxy-7-methyl-, (s)-
nsc 406035
9,2-(methylenedioxy)aporphine
nsc-406035
eximine
6a.alpha.-aporphine,10-dimethoxy-1,2-(methylenedioxy)-
dicentrine-(+)
NSC406035 ,
517-66-8
dicentrine
5h-benzo[g]-1,5,4-de]quinoline, 6,7,7a,8-tetrahydro-10,11-dimethoxy-7-methyl-, (s)-
o,n-dimethyllitseferine
C17426
chebi:81079 ,
CHEMBL464748 ,
bdbm50306885
4-27-00-06486 (beilstein handbook reference)
j2zgt5m0n7 ,
unii-j2zgt5m0n7
SCHEMBL6369440
(+)-dicentrine
9,10-dimethoxy-1,2-(methylenedioxy)-6a.alpha.-aporphine
dicentrine d-form [mi]
dicentrine [mi]
dicentrine, (+)-
5h-benzo(g)-1,3-benzodioxolo(6,5,4-de)quinoline, 6,7,7a,8-tetrahydro-10,11-dimethoxy-7-methyl-, (7as)-
dicentrin
Q-100578
5h-benzo[g]-1,3-benzodioxolo[6,5,4-de]quinoline, 6,7,7a,8-tetrahydro-10,11-dimethoxy-7-methyl-, (s)-
10,11-dimethoxy-7-methyl-6,7,7a,8-tetrahydro-5h-[1,3]benzodioxolo[6,5,4-de]benzo[g]quinoline-, (s)-
YJWBWQWUHVXPNC-AWEZNQCLSA-N
DTXSID10199651
(s)-form;(+)-dicentrine
AKOS037514612
HY-N6969
Q15410930
CS-0026026
(12s)-16,17-dimethoxy-11-methyl-3,5-dioxa-11-azapentacyclo[10.7.1.02,6.08,20.014,19]icosa-1(20),2(6),7,14,16,18-hexaene
5h-benzo(g)-1,3-benzodioxolo(6,5,4-de)quinoline, 6,7,7a,8-tetrahydro-10,11-dimethoxy-7-methyl-, (s)- (9ci)
MS-25168
NSC251699 ,
nsc-251699
5h-benzo[g]-1,5,4-de]quinoline, 6,7,7a,8-tetrahydro-10,11-dimethoxy-7-methyl-, (r)-
dicentrine-(-)
NCI60_002017
smr000156300
MLS000575015 ,
(-)-dicentrine
CHEMBL478754
NCGC00247614-01
HMS2223B12
(r)-(-)-dicentrine
nsc 251699
unii-5o9kk11109
5o9kk11109 ,
dicentrine l-form [mi]
dicentrine, (-)-
5h-benzo(g)-1,3-benzodioxolo(6,5,4-de)quinoline, 6,7,7a,8-tetrahydro-10,11-dimethoxy-7-methyl-, (7ar)-
bdbm70841
cid_317843
Q27262635
(r)-10,11-dimethoxy-7-methyl-6,7,7a,8-tetrahydro-5h-[1,3]dioxolo[4',5':4,5]benzo[1,2,3-de]benzo[g]quinoline
(12r)-16,17-dimethoxy-11-methyl-3,5-dioxa-11-azapentacyclo[10.7.1.02,6.08,20.014,19]icosa-1(20),2(6),7,14,16,18-hexaene
AKOS040744558

Research Excerpts

Overview

Dicentrine is an antiplatelet agent isolated from the Chinese herb Lindera megaphylla. Dicentrine was found to be a potent alpha 1-adrenoceptor blocking agent in rat thoracic aorta as revealed by its competitive antagonism of noradrenaline or phenylephrine.

ExcerptReferenceRelevance
"Dicentrine is a known alpha 1-adrenoceptor antagonist, but its alpha 1-adrenoceptor subtype selectivity has not yet been determined. "( Dicentrine is preferentially antagonistic to rat aortic than splenic alpha 1-adrenoceptor stimulation.
Achike, FI; Mustafa, MR, 2000
)
3.19
"Dicentrine is an alpha 1-adrenoceptor antagonist which is more selective towards the putative alpha 1D-adrenoceptor subtype of the rat aorta than the alpha 1B-adrenoceptor of the spleen."( Dicentrine is preferentially antagonistic to rat aortic than splenic alpha 1-adrenoceptor stimulation.
Achike, FI; Mustafa, MR, 2000
)
3.19
"Dicentrine is an antiplatelet agent isolated from the Chinese herb Lindera megaphylla. "( Dicentrine, a novel antiplatelet agent inhibiting thromboxane formation and increasing the cyclic AMP level of rabbit platelets.
Chen, CC; Huang, TF; Huang, YL; Ko, FN; Teng, CM; Yu, SM, 1992
)
3.17
"2. Dicentrine was found to be a potent alpha 1-adrenoceptor blocking agent in rat thoracic aorta as revealed by its competitive antagonism of noradrenaline- (pA2 = 8.19 +/- 0.09) or phenylephrine (pA2 = 9.01 +/- 0.10)-induced vasoconstriction."( Dicentrine, a natural vascular alpha 1-adrenoceptor antagonist, isolated from Lindera megaphylla.
Chen, CC; Huang, TF; Huang, YL; Ko, FN; Teng, CM; Yu, SM, 1991
)
2.24
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aporphine alkaloidAny benzylisoquinoline alkaloid that has a structure based on 4H-dibenzo[de,g]quinoline or its 3-methyl derivative.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (34)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency4.46680.044717.8581100.0000AID485294
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency0.50000.140911.194039.8107AID2451
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency50.11870.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency31.62280.177814.390939.8107AID2147
WRNHomo sapiens (human)Potency56.23410.168331.2583100.0000AID651768
USP1 protein, partialHomo sapiens (human)Potency22.38720.031637.5844354.8130AID743255
TDP1 proteinHomo sapiens (human)Potency4.36020.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency15.84890.180013.557439.8107AID1460
67.9K proteinVaccinia virusPotency2.51190.00018.4406100.0000AID720579
IDH1Homo sapiens (human)Potency32.64270.005210.865235.4813AID686970
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency16.36010.00419.984825.9290AID504444
importin subunit beta-1 isoform 1Homo sapiens (human)Potency70.79465.804836.130665.1308AID540263
DNA polymerase betaHomo sapiens (human)Potency56.23410.022421.010289.1251AID485314
flap endonuclease 1Homo sapiens (human)Potency18.15990.133725.412989.1251AID588795; AID720498
snurportin-1Homo sapiens (human)Potency70.79465.804836.130665.1308AID540263
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency31.62280.010323.856763.0957AID2662
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency2.81840.050127.073689.1251AID588590
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency10.00000.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency10.00000.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency10.00000.15855.287912.5893AID540303
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency24.03530.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency24.84460.004611.374133.4983AID624296; AID624297
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency79.43280.00419.962528.1838AID2675
lamin isoform A-delta10Homo sapiens (human)Potency11.22020.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cyclin-dependent kinase 2Homo sapiens (human)IC50 (µMol)50.00000.00041.044410.0000AID457604
tyrosyl-DNA phosphodiesterase 2Homo sapiens (human)IC50 (µMol)7.82800.16113.96438.0090AID743297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
recombinase AMycobacterium tuberculosis H37RvEC50 (µMol)11.00600.018023.2882287.6000AID434968; AID435010
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
aryl hydrocarbon receptor nuclear translocatorHomo sapiens (human)AC5017.62000.190023.3694115.5100AID651703
Caspase 6, apoptosis-related cysteine peptidaseHomo sapiens (human)AC505.63000.063611.235844.9700AID720632
transforming acidic coiled-coil-containing protein 3Homo sapiens (human)AC5017.62000.190024.2333115.5100AID651703
dual specificity tyrosine-phosphorylation-regulated kinase 1ARattus norvegicus (Norway rat)AC502.08700.00564.693226.6940AID588345
glycogen synthase kinase-3 alphaHomo sapiens (human)AC5024.93000.013529.7434171.7000AID463203
replicative DNA helicaseMycobacterium tuberculosis H37RvAC5038.76000.057030.7482325.3000AID449749; AID449750
DNA repair protein RAD52 homolog isoform aHomo sapiens (human)AC501.18000.150012.066235.2100AID652116
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (31)

Processvia Protein(s)Taxonomy
G1/S transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
G2/M transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICyclin-dependent kinase 2Homo sapiens (human)
DNA replicationCyclin-dependent kinase 2Homo sapiens (human)
DNA repairCyclin-dependent kinase 2Homo sapiens (human)
chromatin remodelingCyclin-dependent kinase 2Homo sapiens (human)
DNA-templated transcriptionCyclin-dependent kinase 2Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 2Homo sapiens (human)
potassium ion transportCyclin-dependent kinase 2Homo sapiens (human)
centriole replicationCyclin-dependent kinase 2Homo sapiens (human)
Ras protein signal transductionCyclin-dependent kinase 2Homo sapiens (human)
regulation of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of cell population proliferationCyclin-dependent kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of heterochromatin formationCyclin-dependent kinase 2Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA-templated DNA replication initiationCyclin-dependent kinase 2Homo sapiens (human)
telomere maintenance in response to DNA damageCyclin-dependent kinase 2Homo sapiens (human)
post-translational protein modificationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA replicationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionCyclin-dependent kinase 2Homo sapiens (human)
centrosome duplicationCyclin-dependent kinase 2Homo sapiens (human)
cell divisionCyclin-dependent kinase 2Homo sapiens (human)
meiotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
cellular response to nitric oxideCyclin-dependent kinase 2Homo sapiens (human)
cellular senescenceCyclin-dependent kinase 2Homo sapiens (human)
regulation of anaphase-promoting complex-dependent catabolic processCyclin-dependent kinase 2Homo sapiens (human)
regulation of G2/M transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
signal transductionCyclin-dependent kinase 2Homo sapiens (human)
regulation of gene expressionCyclin-dependent kinase 2Homo sapiens (human)
response to organic substanceCyclin-dependent kinase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
histone kinase activityCyclin-dependent kinase 2Homo sapiens (human)
magnesium ion bindingCyclin-dependent kinase 2Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
protein bindingCyclin-dependent kinase 2Homo sapiens (human)
ATP bindingCyclin-dependent kinase 2Homo sapiens (human)
protein domain specific bindingCyclin-dependent kinase 2Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein kinase activityCyclin-dependent kinase 2Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
chromosome, telomeric regionCyclin-dependent kinase 2Homo sapiens (human)
condensed chromosomeCyclin-dependent kinase 2Homo sapiens (human)
X chromosomeCyclin-dependent kinase 2Homo sapiens (human)
Y chromosomeCyclin-dependent kinase 2Homo sapiens (human)
male germ cell nucleusCyclin-dependent kinase 2Homo sapiens (human)
nucleusCyclin-dependent kinase 2Homo sapiens (human)
nuclear envelopeCyclin-dependent kinase 2Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 2Homo sapiens (human)
cytoplasmCyclin-dependent kinase 2Homo sapiens (human)
endosomeCyclin-dependent kinase 2Homo sapiens (human)
centrosomeCyclin-dependent kinase 2Homo sapiens (human)
cytosolCyclin-dependent kinase 2Homo sapiens (human)
Cajal bodyCyclin-dependent kinase 2Homo sapiens (human)
cyclin A1-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin A2-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin E1-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin E2-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 2Homo sapiens (human)
transcription regulator complexCyclin-dependent kinase 2Homo sapiens (human)
cytoplasmCyclin-dependent kinase 2Homo sapiens (human)
nucleusCyclin-dependent kinase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (51)

Assay IDTitleYearJournalArticle
AID328637Vasorelaxation activity in Sprague-Dawley rat aortic assessed as inhibition of phenylephrin-induced contraction2008Journal of natural products, Feb, Volume: 71, Issue:2
Vasorelaxing alkaloids and flavonoids from Cassytha filiformis.
AID398837Antiplatelet activity against arachidonic acid-induced rabbit platelet aggregation assessed as platelet aggregation at 10 ug/ml preincubated for 3 mins by turbidimetric method relative to control1997Journal of natural products, Jun, Volume: 60, Issue:6
Bioactive alkaloids from Illigera luzonensis.
AID398846Antiplatelet activity against arachidonic acid-induced rabbit platelet aggregation assessed as platelet aggregation at 2 ug/ml preincubated for 3 mins by turbidimetric method relative to control1997Journal of natural products, Jun, Volume: 60, Issue:6
Bioactive alkaloids from Illigera luzonensis.
AID403983Antiplatelet activity against collagen-induced rabbit platelet aggregation assessed as platelet aggregation at 100 ug/ml preincubated for 3 mins by turbidimetric method relative to control1997Journal of natural products, Jun, Volume: 60, Issue:6
Bioactive alkaloids from Illigera luzonensis.
AID1540230Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay
AID398836Antiplatelet activity against arachidonic acid-induced rabbit platelet aggregation assessed as platelet aggregation at 20 ug/ml preincubated for 3 mins by turbidimetric method relative to control1997Journal of natural products, Jun, Volume: 60, Issue:6
Bioactive alkaloids from Illigera luzonensis.
AID379269Growth inhibition of Saccharomyces cerevisiae RS321 after 48 hrs by XTT assay2000Journal of natural products, Feb, Volume: 63, Issue:2
Isolation and biochemical characterization of a new topoisomerase I inhibitor from Ocotea leucoxylon.
AID1540231Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay
AID1540229Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay
AID403982Antiplatelet activity against arachidonic acid-induced rabbit platelet aggregation assessed as platelet aggregation at 100 ug/ml preincubated for 3 mins by turbidimetric method relative to control1997Journal of natural products, Jun, Volume: 60, Issue:6
Bioactive alkaloids from Illigera luzonensis.
AID379268Growth inhibition of Saccharomyces cerevisiae RS322 after 48 hrs by XTT assay2000Journal of natural products, Feb, Volume: 63, Issue:2
Isolation and biochemical characterization of a new topoisomerase I inhibitor from Ocotea leucoxylon.
AID379270Growth inhibition of Saccharomyces cerevisiae RJ03 after 48 hrs by XTT assay2000Journal of natural products, Feb, Volume: 63, Issue:2
Isolation and biochemical characterization of a new topoisomerase I inhibitor from Ocotea leucoxylon.
AID398830Antiplatelet activity against PAF-induced rabbit platelet aggregation assessed as platelet aggregation at 100 ug/ml preincubated for 3 mins by turbidimetric method relative to control1997Journal of natural products, Jun, Volume: 60, Issue:6
Bioactive alkaloids from Illigera luzonensis.
AID398838Antiplatelet activity against arachidonic acid-induced rabbit platelet aggregation assessed as platelet aggregation at 5 ug/ml preincubated for 3 mins by turbidimetric method relative to control1997Journal of natural products, Jun, Volume: 60, Issue:6
Bioactive alkaloids from Illigera luzonensis.
AID1540227Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay
AID457604Inhibition of CDK22010Bioorganic & medicinal chemistry letters, Feb-15, Volume: 20, Issue:4
Semi-synthetic aristolactams--inhibitors of CDK2 enzyme.
AID403981Antiplatelet activity against ADP-induced rabbit platelet aggregation assessed as platelet aggregation at 100 ug/ml preincubated for 3 mins by turbidimetric method relative to control1997Journal of natural products, Jun, Volume: 60, Issue:6
Bioactive alkaloids from Illigera luzonensis.
AID1540228Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745849Viability Counterscreen for CMV-Luciferase Assay of Inhibitors of ATXN expression
AID1745848Confirmatory qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1745850Viability Counterscreen for Confirmatory qHTS for Inhibitors of ATXN expression
AID1745847CMV-Luciferase Counterscreen for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID335147Cytotoxicity against human A431 cells after 3 days by SRB assay1993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID335142Cytotoxicity against human SK-MEL-2 cells after 3 days by SRB assay1993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID335146Cytotoxicity against mouse P388 cells after 3 days by SRB assay1993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID335152Antimalarial activity after 24 hrs against chloroquine-resistant Plasmodium falciparum W2 infected type A+ human erythrocytes by [3H]hypoxanthine uptake1993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID335153Selectivity index, ED50 for human KB cells to ED50 for chloroquine-sensitive Plasmodium falciparum D61993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID335141Cytotoxicity against human LUC1 cells after 3 days by SRB assay1993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID335148Cytotoxicity against human LNCAP cells after 3 days by SRB assay1993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID335149Cytotoxicity against human ZR-75-1 cells after 3 days by SRB assay1993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID335154Selectivity index, ED50 for human KB cells to ED50 for chloroquine-resistant Plasmodium falciparum W21993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID335150Cytotoxicity against human U373 cells after 3 days by SRB assay1993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID335145Cytotoxicity against vinblastine-resistant human KBV1 cells after 3 days by SRB assay1993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID335140Cytotoxicity against human HT1080 cells after 3 days by SRB assay1993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID335139Cytotoxicity against human BCA1 cells after 3 days by SRB assay1993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID335144Cytotoxicity against human KB cells after 3 days by SRB assay1993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID335151Antimalarial activity after 24 hrs against chloroquine-sensitive Plasmodium falciparum D6 infected type A+ human erythrocytes by [3H]hypoxanthine uptake1993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
AID335143Cytotoxicity against human Col1 cells after 3 days by SRB assay1993Journal of natural products, Sep, Volume: 56, Issue:9
Cytotoxic and antimalarial alkaloids from the tubers of Stephania pierrei.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (41)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's15 (36.59)18.2507
2000's8 (19.51)29.6817
2010's16 (39.02)24.3611
2020's2 (4.88)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 48.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index48.98 (24.57)
Research Supply Index3.61 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index76.15 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (48.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews1 (2.78%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other35 (97.22%)84.16%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]